IRLAB Therapeutics AB Class A (DE:6IRA)
FRANKFURT:6IRA
Want to see DE:6IRA full AI Analyst Report?
Total Valuation
IRLAB Therapeutics AB Class A has a market cap or net worth of €10.07M. The enterprise value is €83.39M.
Market Cap€10.07M
Enterprise Value€83.39M
Share Statistics
IRLAB Therapeutics AB Class A has 84,858,246 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding84,858,246
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
IRLAB Therapeutics AB Class A’s return on equity (ROE) is -3.58 and return on invested capital (ROIC) is -152.21%.
Return on Equity (ROE)-3.58
Return on Assets (ROA)-0.80
Return on Invested Capital (ROIC)-152.21%
Return on Capital Employed (ROCE)-3.01
Revenue Per Employee1.85M
Profits Per Employee-3.55M
Employee Count31
Asset Turnover0.42
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of IRLAB Therapeutics AB Class A is 3.4. IRLAB Therapeutics AB Class A’s PEG ratio is -0.48.
PE Ratio3.4
PS Ratio2.30
PB Ratio4.30
Price to Fair Value4.30
Price to FCF-2.39
Price to Operating Cash Flow-1.15
PEG Ratio-0.48
Income Statement
In the last 12 months, IRLAB Therapeutics AB Class A had revenue of 57.46M and earned -110.01M in profits. Earnings per share was -1.64.
Revenue57.46M
Gross Profit-92.35M
Operating Income-92.35M
Pretax Income-110.01M
Net Income-110.01M
EBITDA-88.03M
Earnings Per Share (EPS)-1.64
Cash Flow
In the last 12 months, operating cash flow was -90.23M and capital expenditures 0.00, giving a free cash flow of -90.23M billion.
Operating Cash Flow-90.23M
Free Cash Flow-90.23M
Free Cash Flow per Share-1.06
Dividends & Yields
IRLAB Therapeutics AB Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.06
52-Week Price Change-81.09%
50-Day Moving Average0.13
200-Day Moving Average0.19
Relative Strength Index (RSI)47.93
Average Volume (3m)0.00
Important Dates
IRLAB Therapeutics AB Class A upcoming earnings date is Aug 26, 2026, TBA (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 26, 2026
Ex-Dividend Date―
Financial Position
IRLAB Therapeutics AB Class A as a current ratio of 0.80, with Debt / Equity ratio of 67.98%
Current Ratio0.80
Quick Ratio0.80
Debt to Market Cap0.20
Net Debt to EBITDA0.59
Interest Coverage Ratio-5.13
Taxes
In the past 12 months, IRLAB Therapeutics AB Class A has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
IRLAB Therapeutics AB Class A EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -1.45.
EV to Sales1.39
EV to EBITDA-0.91
EV to Free Cash Flow-1.45
EV to Operating Cash Flow-1.45
Balance Sheet
IRLAB Therapeutics AB Class A has €50.79M in cash and marketable securities with €27.08M in debt, giving a net cash position of €23.70M billion.
Cash & Marketable Securities€50.79M
Total Debt€27.08M
Net Cash€23.70M
Net Cash Per Share€0.28
Tangible Book Value Per Share-€0.24
Margins
Gross margin is -42.97%, with operating margin of -160.71%, and net profit margin of -191.45%.
Gross Margin-42.97%
Operating Margin-160.71%
Pretax Margin-191.45%
Net Profit Margin-191.45%
EBITDA Margin-153.20%
EBIT Margin-160.71%
Analyst Forecast
The average price target for IRLAB Therapeutics AB Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-1.34%
EPS Growth Forecast24.78%